Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

Jennifer Woyach, MD
Published: Wednesday, Dec 07, 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.
The study includes 4 cohorts of patients – including patients with relapse/refractory CLL, treatment naïve CLL, richter’s transformation, and patients who have received treatment with ibrutinib (Imbruvica) and have developed mutations that will render them resistant to ibrutinib without having clinical progression, Woyach says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication